Peng-Yu Chen Zi-Yun Li Sui-Qing Cai
10.3389/fimmu.2023.1188523
Front Immunol
2023 Aug 3;14:1188523.
adalimumab cadonilimab/ak104 case report immune checkpoint inhibitor immune-related adverse events toxic epidermal necrolysis
CC BY
https://pubmed.ncbi.nlm.nih.gov/37600791/
Carcinoma, Hepatocellular / drug therapy Chemoembolization, Therapeutic Liver Neoplasms Stevens-Johnson Syndrome / diagnosis Stevens-Johnson Syndrome / drug therapy Stevens-Johnson Syndrome / etiology
Carcinoma, Hepatocellular / drug therapy Chemoembolization, Therapeutic Liver Neoplasms Stevens-Johnson Syndrome / diagnosis Stevens-Johnson Syndrome / drug therapy Stevens-Johnson Syndrome / etiology Case Reports Research Support, Non-U.S. Gov't Adalimumab / adverse effects Humans Adalimumab
PMC10435079
37600791
Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab
2023